Lifecore reports FY 2024 revenue $128.3M (+24.2%), Adj. EBITDA $20.2M; FY25 rev guidance $126.5-130M

LIFECORE BIOMEDICAL, INC. DE

2025-Q1 EPS reported -$0.53 vs consensus -$0.15 ▼ miss (-246.4%)

FY 2024 revenue $128.3M (+24.2% YoY); Q4 revenue $37.9M (+21.6% YoY).
FY 2024 net income $9.3M (incl. $39.5M non-cash gain) vs loss $64.2M; Adj. EBITDA $20.2M.
Q4 net loss $7.1M vs $37.0M (prior yr had $23.7M debt extinguish loss); Adj. EBITDA $10.4M.
FY 2025 guidance: rev $126.5-130M, Adj. EBITDA $19-21M, capex $10-14M.
5-head isolator filler GMP-ready Sept 2024; headcount reduced in July; SEC filings current.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.